Company News: Curetis Announces Excellent Study Data and Multi-Region Launch of Unyvero BCU Blood Culture Application Cartridge

– Interim data from prospective multicenter evaluation show 98% concordance with conventional microbiology

– Unyvero results on average available 24 hours earlier than in conventional microbiology, enabling rapid decision on appropriate antibiotic therapy

Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the broad commercial roll-out of its new Unyvero BCU Blood Culture Application Cartridge, which was introduced during ECCMID in April 2016. The roll-out has been initiated in Europe, the Middle East and Asia via Curetis’ internal sales force and the company’s distribution partner network.

The market launch is supported by excellent interim data from an external, prospective, multicenter evaluation comparing the performance of the BCU Application Cartridge against the performance of conventional microbiology work-up of positive blood cultures that is ongoing at three European hospitals.

The interim analysis on approximately 100 patient samples demonstrated a 98% concordance with conventional microbiology. Additional pathogens that escaped detection by conventional microbiology were found in several cases. On average, Unyvero results were available 24 hours earlier and in some cases up to two days earlier than results obtained by routine diagnostic methods. The data also confirm compatibility with most commonly used blood culture systems, namely BacT/ALERT® (BioMérieux) and BD BACTEC™ (Becton Dickinson).

Curetis expects to finalize the prospective evaluation during the third quarter of 2016 and is planning to submit a joint publication with the clinical investigators of the study to a peer-reviewed medical journal.

“The new Unyvero Application for blood cultures has truly proven its worth in our microbiology laboratory, thanks to its broad coverage of pathogens, the identification of antibiotic resistances and its easy handling,” said Dr. Monika Huber, senior physician and private lecturer of the Institute of Pathology and Bacteriology, at SMZ Otto Wagner Spital in Vienna, Austria, one of the clinical investigators of the study. “Even with mixed infections, excellent results are obtained within a few hours – a very valuable time gain for bringing adequate therapy to the patient.”

“We are very pleased with these first data from the prospective evaluation of our BCU Blood Culture Application,” said Dr. Achim Plum, CCO of Curetis, “They demonstrate the versatility and utility of our new BCU Application Cartridge in the rapid and reliable identification of pathogens and antibiotic resistance markers in positively flagged blood cultures. The results also indicate its significant potential to improve the management of critically ill patients with blood stream infections.”